An observational study in Aortic Valve Stenosis and Transcatheter Aortic Valve Replacement, sponsored by Niguarda Hospital. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-16.
Sponsored by Niguarda Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Aortic Valve Stenosis with a site in Italy — 39 open to participants now, 54 under way, 1 of them phase 3. Aortic Valve Stenosis · Italy.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, this one is the 64th largest by planned enrollment of the 71 observational ones that give a count, is one of 10 that started in 2023, is one of 71 observational ones, reaches primary completion later than 32 of the 53 other live ones, and was the 86th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →39 of the 118 studies in Aortic Valve Stenosis with a site in Italy are open now. Recruiting first, the newest first:
University Hospital of Ferrara · Sites in Italy
Ages 75+
University Hospital of Ferrara · Sites in Italy
Azienda Ospedaliera "Sant'Andrea" · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
IRCCS Policlinico S. Donato · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 10 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is below the median of 200 across 437 observational studies indexed under Aortic Valve Stenosis.
Median enrollment 300 across the 47 interventional studies, 500 across the 71 observational. Of the 53 that completed or were terminated, 15 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
52 of 118 have an industry lead sponsor. The 10 most frequent:
Niguarda Hospital is the lead sponsor of 68 studies on the registry; 29 are open to participants now.
Niguarda Hospital has 3 studies filed under Aortic Valve Stenosis — fewer than ten, so there is no comparison to draw.
9 of the studies in Aortic Valve Stenosis with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07620925Azienda Ospedaliera "Sant'Andrea"Derivation and Validation of the Aortic Valve Echocardiographic Calcium Score to Confirm Severe Aortic Stenosis: the Echo-AVCS Study | 2026-12-31 |
| NCT06859255IRCCS Policlinico S. DonatoIn-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic Stenosis With Small Annulus, Followed by In-vivo Validation | 2027-02-07 |
| NCT05779787Niguarda HospitalCOronary Re-engageMent aFter randOm NavitoR alignmenT (COMFORT STUDY) | 2027-02-15 |
| NCT05751577Azienda Usl di BolognaTRanscatheter Aortic-Valve Implantation With or Without On-site Cardiac Surgery: the TRACS Trial | 2027-03-31 |
| NCT05932615Abbott Medical DevicesENVISION IDE Trial: Safety and Effectiveness of NAVITOR in Transcatheter Aortic Valve Implantation | 2027-04 |
Add all 9 to your calendar (.ics) → With an account.
Among the 118 studies in Aortic Valve Stenosis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Whereas PCI before TAVR was previously recommended despite its uncertain prognostic role, recent data underline the possibility of a postponed coronary intervention using a commissural alignment technique. This approach allows easy coronary re-engagement through the valve stent frame with a trade off paid of procedure complexity.
Considering the prevalence of coronary artery disease (CAD) and the increasing percentage of younger patients treated with TAVI, investigate whether a simpler procedure with random implantation of Navitor valve is not inferior in terms of coronary re-access, is required The key point of the project will be the evaluation of the feasibility of coronary re-engagement after a Navitor valve randomly implanted.
Transcatheter Aortic Valve Implantation (TAVI) is recommended by European and American guidelines to treat patients with aortic stenosis regardless of procedural risk (1, 2). In the last decades the increasing percentage of younger patients treated with TAVI, reflect the extensive indications in lower risk setting, highlighting the importance of easy coronary re-engagement after valve implantation. Considering the prevalence and the progression of a pre-existing coronary artery disease (CAD), the timing of coronary intervention should be accurate selected (3) addressing the percentage of unplanned percutaneous coronary intervention (PCI) after TAVI (4). In fact, while PCI before TAVR was previously recommend despite the uncertain prognostic role (5), recent data remarks the possibility of a postponed coronary intervention using a commissural alignment technique (6) that allows a predictable stent frame position in the sinus of Valsalva (7). Moreover, following the emerging concept of easy re-access, only a few types of prostheses have been shown to have an high degree of stent position predictability after implantation, leading to a limited option in terms of prosthesis choice. Furthermore, to achieve the best results with commissural alignment technique, accurate procedure planning and operator's expertise are required in order to properly manage the valve specific orientation in the aorta with consequent increase in time, radiation and procedure complexity.
However, geometry of the stent frame (height and size) and the anatomical characteristics of patients have to be enlisted as contributory factors to difficult coronary re-engagement and need to be evaluate in order to establish the feasibility of the re-access after TAVR.
The investigators' findings could provide data regarding the non-inferiority rate of coronary cannulation after a simpler procedure with Navitor implantation without alignment technique. Due to these results, the valves portfolio available in patients with coronary artery disease that needed PCI after TAVR, could be larger and various allowing the best protheses choice according to the patient's anatomy and operator's expertise. Finally, knowing the predictors of difficult re-engagement for both types of valves, regardless of implantation technique, could be interesting for an even more valve tailored approach.
The purpose of this study is to investigate the feasibility of coronary re-engagement after randomly (not aligned) Navitor implantation, as already perform in current clinical practice, due to a lower predictable orientation of this type of valve.
Consecutive patients with severe aortic stenosis diagnosed according to ESC guidelines, undergoing transcatheters aortic valve replacement with Navitor valve randomly implanted or Acurate Neo with commisural alignment technique
Patients to be included in this registry should have all the following criteria:
1. Severe, symptomatic aortic stenosis with an indication to TAVI
Exclusion criteria and definition
Patients excluded in this registry should have all the following criteria:
Patients with severe aortic stenosis undergoing TAVR procedure performed with commissural alignment technique. We consider in this groups only the Accurate and Accurate Neo 2 Valve which are the first choice due to the best stent frames position predictability with this technique
Procedure: TAVR Aligned · Procedure: TAVR Random
Patients with severe aortic stenosis undergoing TAVR procedure performed with random implantation of Navitor Valve
Procedure: TAVR Aligned · Procedure: TAVR Random
Investigate the feasibility of coronary re-engagement after commissural alignment technique in terms of success rate (%) and procedure complexity taking into account radiations, time and contrast used.
TAVR Random Feasibility comparison of coronary re-engagement between the randomly implanted Navitor valve (unaligned) and the others implanted with the commissural alignment technique in terms of success rate (%) and complexity of the procedure, taking into account radiation, time and contrast used
Coronary re-access after TAVR procedure
Re-engagement of LMCA and RCA after valve implantation is defined as selective cannulation and subsequent selective angiography. All others type of re-engagement will be classify as "non selective". We will stratify also the modality of re-cannulation in relation to the position of the valves' stent struts as "above", "across" and "behind".
Time frame: During procedure
Total Implant Time
Total time required for valve implantation. We count the time from the alignment in the aorta to the end of valve opening (Alignment Fluoroscopy time + Implantation Fluoroscopy time).
Time frame: During procedure
Total Implant Fluoroscopy Time
Total Fluoroscopy time required for valve implantation. We count the time from the alignment in the aorta to the end of valve opening (Alignment time + Implantation time).
Time frame: During procedure
Total Implant Radiations
Total Radiations required for valve implantation. We count the radiations used from the alignment in the aorta to the end of valve opening (Alignment time + Implantation time).
Time frame: During procedure
Total Implant Contrast
Total Contrast required for valve implantation
Time frame: During procedure
Alignment Radiation
Radiation required for commissural alignment
Time frame: During procedure
Alignment Fluoroscopy Time
Fluoroscopy time required for commissural alignment
Time frame: During procedure
Implant Radiation
Radiation required for valve implantation
Time frame: During procedure
Implant Fluoroscopy Time
Fluoroscopy time required for valve implantation
Time frame: During procedure
Implant Contrast
Contrast required for valve implantation
Time frame: During procedure
Re-Engagement Radiation
Radiation required for re-engagement
Time frame: During procedure
Re-Engagement Fluoroscopy Time
Fluoroscopy time required for coronary re-engagement
Time frame: During procedure
Re-Engagement Contrast used
Contrast required for coronary re-engagement
Time frame: During procedure
Re-Engagement Time
Time required for coronary re-engagement
Time frame: During procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2023 (actual). Primary completion is estimated for Feb 2027, 48 months after the start.
Of 206 non-industry observational studies under Aortic Valve Stenosis, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 120. This study's planned 48 months is close to that.
Counting every sponsor, half of 243 studies reached it within 44 months; a quarter within 23 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Niguarda Hospital